Skip to main content

Advertisement

SpringerLink
Log in

A new combined vaccine against measles, mumps, rubella and varicella in India

  • Drug Review
  • Published:
Indian Pediatrics Aims and scope Submit manuscript

Abstract

A quadrivalent MMRV (measles-mumps-rubella-varicella) combination vaccine has recently been launched in India. This vaccine is highly immunogenic, with seroconversion rates against all antigens reaching 96.6-100% at 42 to 56 days after the second vaccine dose in unvaccinated children or in those previously vaccinated with MMR+/-V. Two doses efficacy, against all varicella is 94.1% and effectiveness reaches 91%. The most frequent solicited local adverse event after MMRV vaccine is redness, and fever is the most common solicited general symptom. Higher rates of fever and febrile convulsions compared to MMR+/-V have been reported when used as first dose but not when used as the second of a measles containing vaccine, irrespective of age of the second dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organisation. Mumps Virus Vaccines: WHO Position Paper. Wkly Epidemiol Rec. 2007;82:51-60.

  2. World Health Organisation. Measles Vaccines: WHO Position Paper. Wkly Epidemiol Rec. 2009;84:349-60.

  3. World Health Organisation. Rubella Vaccines: WHO Position Paper. Wkly Epidemiol Rec. 2011;86:301-16.

  4. World Health Organisation. Varicella and Herpes zoster Vaccines: WHO Position Paper. Wkly Epidemiol Rec. 2014;89:265-87.

  5. Historic Dates and Events Related to Vaccines and Immunization. Available from: http://www.immunize.org/timeline/. Accessed July 18, 2016.

  6. World Health Organization. Global Measles and Rubella Strategic Plan, 2012–2020. Geneva; WHO 2012. Available from:http://www.who.int/immunization/documents/control/ISBN_978_92_4_150339_6. Accessed July 18, 2016.

  7. IAP Immunization Timetable 2016. Available from: http://www.iapindia.org/page.php?id=129. Accessed April 13, 2017.

  8. Mathew JL. Evidence-based options to improve routine immunization. Indian Pediatr. 2009;46:993–6.

    PubMed  Google Scholar 

  9. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496–500.

    Article  PubMed  Google Scholar 

  10. Ma SJ, Li X, Xiong YQ, Yao AL, Chen Q. Combination measles-mumps-rubella-varicella vaccine in healthy children: A systematic review and meta-analysis of immunogenicity and safety. Medicine. 2015;94:e1721.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): Immunogenicity and safety profile. Vaccine. 2009;27:6504–11.

    Article  CAS  PubMed  Google Scholar 

  12. Priorix Tetra Full Prescribing Information Version PRT/PI/IN/2017/02. Available from: GlaxoSmithKline Pharmaceuticals Ltd Dr. Annie Besant Road, Worli, Mumbai-400030 (India).

  13. Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow HM, et al. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. Eur J Pediatr. 2010;169:925–33.

    Article  PubMed  Google Scholar 

  14. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, et al. Immunogenicity and safety assessments after one and two doses of a refrigeratorstable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27:724–30.

    Article  PubMed  Google Scholar 

  15. Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25:12–8.

    Article  PubMed  Google Scholar 

  16. Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, et al. Antibody persistence for 3 years following two doses of tetravalent measles-mumpsrubella-varicella vaccine in healthy children. Eur J Pediatr. 2012;171:463–70.

    Article  CAS  PubMed  Google Scholar 

  17. Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, et al. Safety and immunogenicity of a measlesmumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine. 2009;27:2701–6.

    Article  CAS  PubMed  Google Scholar 

  18. Gillet Y, Steri GC, Behre U, Arsene JP, Lanse X, Helm K, et al. Immunogenicity and safety of measles-mumpsrubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27:446–53.

    Article  CAS  PubMed  Google Scholar 

  19. Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, et al. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumpsrubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial. BMJ Open. 2015;5:e007202.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014;383:1313–24.

    Article  CAS  PubMed  Google Scholar 

  21. Czajka H, Brzostek J, Gabutti G, Gasparini R, Desole MG, Pazdiora P, et al. Comparison of six year efficacy between one or two doses of live varicella virus-containing vaccines: a randomized, placebo-controlled trial. Presented at European Society for Paediatric Infectious Diseases -33rd Annual Meeting. 12-16 May 2015; Leipzig Germany: ESPID-0644.

  22. Spackova M, Wiese-Posselt M, Dehnert M, Matysiak-Klose D, Heininger U, Siedler A. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine. 2010;28:686–91.

    Article  CAS  PubMed  Google Scholar 

  23. Dhillon S, Curran MP. Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra). Paediatr Drugs. 2008;10:337–47.

    Article  PubMed  Google Scholar 

  24. Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32:645–50.

    Article  CAS  PubMed  Google Scholar 

  25. Hense S, Schink T, Garbe E. 2nd immunization against measles, mumps, rubella with MMRV, MMR or MMR+V in Germany and risk of febrile convulsions. Presented at International Society for Pharmacoepidemiology -29th International Conference. 25-28 August 2013; Montreal, Canada: ID24.

  26. Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and Reports. 2010;59:1–12.

    PubMed  Google Scholar 

  27. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute–2016/ 2017. Epidemiologisches Bulletin. 2016;34:301-38.

  28. Measles, Mumps, Rubella, Varicella Vaccine -Information for health professionals. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/IT0167-cnt/$File/final-mmrvprovider-booklet.pdf. Accessed April 21, 2017.

  29. Zepp F, Behre U, Kindler K, Laakmann KH, Pankow-Culot H, Mannhardt-Laakmann W, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubellavaricella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr. 2007;166:857–64.

    Article  PubMed  Google Scholar 

  30. Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006;25:287–92.

    Article  PubMed  Google Scholar 

  31. Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J. 2010;29:e47–56.

    Article  PubMed  Google Scholar 

  32. Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumpsrubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine. 2011;29: 4274–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PD Hinduja National Hospital, Mumbai, India

    Nitin Shah

  2. PD Hinduja National Hospital, GSK, Dr Annie Besant Rd, 400030, Mumbai, India

    Raunak Parikh & Shafi Kolhapure

  3. PD Hinduja National Hospital, GSK, Wavre, Belgium

    Giacomo Casabona

Authors
  1. Nitin Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raunak Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giacomo Casabona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shafi Kolhapure
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shah, N., Parikh, R., Casabona, G. et al. A new combined vaccine against measles, mumps, rubella and varicella in India. Indian Pediatr 54, 1041–1046 (2017). https://doi.org/10.1007/s13312-017-1209-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13312-017-1209-9

Keywords

Search

Navigation